Breaking News

WuXi Receives First Approval from Japanese Regulatory Authorities

Subsidiary STA will manufacture intermediate of a branded commercial drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi PharmaTech said that its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co. Ltd. (STA) received its first approval from the Japan PMDA for the manufacture of the GMP intermediate of a branded commercial drug in July. According to the company, STA is now the only Chinese contract manufacturing organization (CMO) to have received approval to supply active pharmaceutical ingredients (APIs) and GMP intermediates for branded commercial drugs fro...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters